Esperion Therapeutics’ shares fall after disclosing uncertain future for its cholesterol-lowering drug

Shares of Esperion Therapeutics’ common stock have plunged this week after the company said the future of its investigational cholesterol-lowering drug remains murky. The FDA told the company that it might require a cardiovascular outcomes study before approving the medication, according to Forbes.

Read more of the article below: